Pregnancy
category N CAS Number 459-02-9 ChemSpider 9592 Molar mass 153.2 g/mol | Routes of
administration oral PubChem CID 9986 Formula C9H12FN | |
 | ||
Legal status CA: Schedule I
DE: Anlage I (Controlled)
UK: Class A | ||
4-Fluoroamphetamine (4-FA; 4-FMP; PAL-303; "Flux"), also known as para-fluoroamphetamine (PFA) is a psychoactive research chemical of the phenethylamine and substituted amphetamine chemical classes. It produces stimulant and entactogenic effects, and is described subjectively as being between amphetamine and MDMA. As a recreational drug, 4-FA is sometimes sold along with related compounds such as 2-fluoroamphetamine and 4-fluoromethamphetamine.
Contents
Usage
4-FA is popular in the Netherlands where it is predominantly used for its specific effects (77% of users) rather than its legal status (18%).
Effects
The subjective effects of 4-fluoroamphetamine include euphoria which some find similar to the effects of MDMA and amphetamine, increased energy (stimulation), mood elevation, feelings of warmth and empathy, excessive talking, bruxism, and suppressed appetite (anorexic). The general course of effects involves primarily empathogenic effects for the first few hours, which fades out as increased stimulation develops over the next several hours.
The dopamine reuptake inhibition produced by 4-FA is stronger than that of either 4-CA or 4-IA. 4-FA also produces less hyperthermia than similar compounds such as PMA, 3-MTA and 4-methylamphetamine.
Common acute side effects are nausea, headaches, increased heart rate and insomnia.
Chemistry
4-FA reacts with reagent tests to give a semi-unique array of colors which can be used to aid its identification.
Pharmacology
4-Fluoroamphetamine is a releasing agent and reuptake inhibitor of dopamine, serotonin, and norepinephrine. The respective EC50 values are 2.0 x 10−7 M, 7.3 x 10−7 M, and 0.37 x 10−7 M, while the IC50 values are 7.7 x 10−7 M, 68 x 10−7 M, and 4.2 x 10−7 M.
Regarding the metabolic fate of 4-FA, the C-F bond at the 4-position on the phenyl ring likely resists deactivation in the liver by cytochrome P450 oxidase.
Neurotoxicity
4-FA does not cause long-lasting depletion of brain serotonin, unlike its analogs 4-CA and 4-BA. This is thought to "reflect the inability of the fluoro-compound to be metabolized in the same way as the other haloamphetamines."
Neurotoxicity does not increase down the series of para-halogenated amphetamine derivatives, even though serotonin releasing potency does follow this trend. For example, 4-iodoamphetamine is less toxic than is 4-chloroamphetamine. Hence, this property is not related to serotonin releasing potency as such, since PAL-287 was reported to be not at all neurotoxic even though it is a powerful 5-HT releasing agent. It is unclear where 4-methylamphetamine fits in on the neurotoxicity scale. The extensive serotonergic neurotoxicity of 4-chloroamphetamine (and its brominated derivative), and the increased serotonergic toxicity of 4-methylamphetamine suggest that para-substitution seems to increase overall serotonergic (neuro)toxicity, compared to amphetamine. Exceptions include 4-MTA, a para-substituted, non-neurotoxic amphetamine.
Toxicology
The LD50 (mouse; i.p.) of 4-FA is 46 mg/kg.
4-FA has only been involved in one death worldwide, where it was combined with amphetamine, methadone and benzodiazepines.
Legal Status
As of October 2015 4-FA is a controlled substance in China.
4-FA is banned in the Czech Republic.
4 FA is also controlled in: Belgium, UK, Germany, Israel, Slovakia, Chile, Brazil, Canada, Croatia, Sweden, USA, New Zealand and France.